反応式
[C:1]([NH:18][C@H:19]([C:26]([OH:28])=[O:27])[CH2:20][C:21]1[N:25]=[CH:24][NH:23][CH:22]=1)(OCC1C2C(=CC=CC=2)C2C1=CC=CC=2)=O.C(N[C@H:47]([C:52]([OH:54])=[O:53])[CH2:48]C(C)C)(OCC1C2C(=CC=CC=2)C2C1=CC=CC=2)=O.S1C=[CH:58][CH:57]=[C:56]1[CH:60]=[O:61].Cl[C:63]1[CH:64]=[C:65]([CH:69]=[CH:70][C:71]=1[Cl:72])[C:66](Cl)=[O:67]>>[Cl:72][C:71]1[CH:70]=[CH:69][C:65]([C:66]([N:18]2[CH:1]([C:60]3[O:61][CH:58]=[CH:57][CH:56]=3)[CH:47]([C:52]([OH:54])=[O:53])[CH2:48][C:19]2([CH2:20][C:21]2[N:25]=[CH:24][NH:23][CH:22]=2)[C:26]([OH:28])=[O:27])=[O:67])=[CH:64][CH:63]=1参加物
5
実験手順
Following the procedure of Example 28(a)-28(d), except beginning with Wang bound Fmoc-L-histidine (Trt) instead of Wang bound Fmoc-L-leucine, and substituting furan-2-carboxaldehyde for thiophene-2-carboxaldehyde, and substituting 4-chlorobenzoylchloride for 3,4-dichlorobenzoyl chloride, the title compound was prepared as a solid. MS [M+H]+444.8
出典と根拠
- ORDレコード
- ord-3adcf0f3a9694e53b5a862322e9894d9
- 出典データセット
- uspto-grants-2004_03
- 特許番号
- US06713502B2
関連ノート
読み込み中…